Feedback / Questions
BT-267 - Brenig Therap
https://www.prnewswire.com/news-releases/brenig-therapeutics-announces-initiation-of-first-in-human-study-of-bt-409-a-brain-selective-nlrp3-inhibitor-and-provides-update-on-bt-267-its-lrrk2-program-302662068.html
Jan 15, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next